论文部分内容阅读
目的:研究低强度华法林抗凝治疗脑卒中风险房颤患者的临床效果。方法:选择2014年12月-2016年12月医院收治的脑卒中风险房颤患者72例,通过随机分组的方法分为对照组与观察组,每组中分别纳入36例患者。对照组患者采用常规阿司匹林治疗,观察组患者采用低强度华法林抗凝治疗。治疗后随访半年,对比两组患者脑血栓发生率,出血并发症发生率。结果:治疗后,观察组患者脑血栓发生率为8.33%,显著低于对照组患者的36.11%(P<0.05)。治疗后,观察组和对照组患者出血并发症发生率分别为16.67%和22.22%,二者相比无显著差异(P>0.05)。结论:在脑卒中风险房颤患者的临床治疗中,采用低强度华法林抗凝治疗的方法,能够取得更为理想的临床疗效。
Objective: To study the clinical effect of low-intensity warfarin anticoagulation in patients with atrial fibrillation at stroke risk. Methods: Seventy-two patients with atrial fibrillation who were admitted to our hospital from December 2014 to December 2016 were randomly divided into control group and observation group. 36 patients were enrolled in each group. Patients in the control group were treated with conventional aspirin, and patients in the observation group were treated with low-intensity warfarin. Follow-up after treatment for six months, compared with two groups of patients with cerebral thrombosis, bleeding complications. Results: After treatment, the incidence of cerebral thrombosis in the observation group was 8.33%, which was significantly lower than that in the control group (36.11%, P <0.05). After treatment, the incidence of bleeding complications in observation group and control group were 16.67% and 22.22% respectively, there was no significant difference between the two groups (P> 0.05). Conclusion: In the clinical treatment of stroke patients with atrial fibrillation risk, the use of low-intensity warfarin anticoagulation therapy can achieve a more satisfactory clinical effect.